Ashland (ASH) Q4 2026 earnings review
Ashland's consumer units grow, but factory snags limit profit
Ashland, a maker of specialty ingredients for medicines, cosmetics and paint, is growing its consumer divisions while factory problems hold back its industrial unit. Fourth-quarter sales rose 4% as volume and prices both climbed, lifting Life Sciences to a record profit margin. However, low output at the Hopewell plant cut Specialty Additives profit by almost a third, so full-year operating profit barely reached the bottom of the company's lowered plan. Higher corporate and restructuring expenses pushed the bottom line into a net loss.
| Sales (Q4) | $498M +4% from a year ago (+3% volume, +2% price) |
|---|---|
| EBITDA, excluding one-offs (Q4) | $121M +2% from a year ago; FY26 hit bottom of $385–400M plan |
| FY27 EBITDA outlook, excluding one-offs | $405–435M +9% at the middle of the range |
| FY27 Cash conversion outlook | >40% down from 60% in FY26 as capex rises to ~$140M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because commercial momentum in drugs and personal care is still offset by factory delays and a weaker cash outlook. Chief executive Guillermo Novo forecasts 9% operating profit growth for fiscal 2027 at the middle of the range, backed by a $45 million target for new products. One caution: the new plan lowers the cash conversion floor to 40% as capital spending climbs to $140 million, and Ashland has cut its initial profit forecast in each of the last two years.
The question now is whether the Hopewell plant fix will finally lift margins in fiscal 2027 or if higher capital spending will eat up the cash gains. Either completed plant upgrades raise production and restore the missing profit, or ongoing factory bottlenecks force a third straight year of lowered targets. Specialty Additives margins in the first half of fiscal 2027 will settle it.
🐂 Bull Case
Drug and Personal Care Ingredients Carry Profit
Ashland's two consumer-facing divisions, Life Sciences (mainly ingredients for medicines) and Personal Care (ingredients for skin, hair and oral care), make up over two-thirds of revenue. Chief executive Guillermo Novo wants these two units to drive steady volume growth while industrial markets lag. Both delivered in the fourth quarter, lifting total company sales volumes by 3% from a year ago.
- Life Sciences sales: $180 million, up 4% from a year ago, with drug ingredient volumes rising for a sixth straight quarter
- Life Sciences EBITDA margin, excluding one-offs: 35.6%, up 3.8 percentage points to "the highest quarterly margin in the segment's history"
- Personal Care sales: $163 million, up 8%, lifting segment EBITDA excluding one-offs by 14% to $49 million
- Coatings and performance specialties (inside Specialty Additives): sales up 9% and 14% on market share gains across all regions
This growth matters because high-margin drug and personal care products are offsetting weak construction demand and factory problems elsewhere. Without the $15 million combined profit increase in these two units, Ashland's total quarterly profit would have fallen instead of rising 2%.
What to watch: Life Sciences volume growth in the first quarter of fiscal 2027. Another gain would show that demand from drugmakers remains strong heading into the new year.
New Products and Markets Beat Targets
"Our globalize and innovate strategies exceeded their full-year targets, driven by deep customer engagement and successful commercialization," chief executive Guillermo Novo said. Globalize is Ashland's push to sell four high-margin product lines — injectables, tablet coatings, biofunctional actives and microbial protection — in more countries, while Innovate covers newly invented chemical platforms.
Each programme brought in $26 million of extra sales in fiscal 2026, beating the $20 million target for Globalize and the $15 million goal for Innovate. Together they added $52 million of revenue, which by our math supplied the company's entire 3% sales increase from businesses owned a year ago. For fiscal 2027, the chemical group plans another $20 million from Globalize and tripled its Innovate target to $45 million.
What to watch: details on the conference call about how much of the $45 million Innovate target comes from newly launched products versus older lines. Clear dollar figures for new launches would confirm that research spending is opening new markets.
Price Increases Now Cover Raw Material Costs
Ashland spent the first half of fiscal 2026 cutting prices by 2% from a year ago while raw material, energy and freight bills stayed volatile. Management began raising prices across its contracts in the spring, aiming to protect profit margins rather than expand them. In the fourth quarter, pricing rose 2% from a year ago, up from a 1% gain in the third quarter.
Novo said the teams executed well, "with pricing actions recovering higher raw material costs" across every business unit. Pricing jumped 5% in both Specialty Additives and Intermediates (industrial solvents) and rose 1% in Life Sciences. Because price increases in chemical contracts take a quarter or two to show up in invoices, this momentum carries into early fiscal 2027, where the outlook assumes pricing will again offset cost inflation.
What to watch: the year-over-year pricing percentage in the first quarter of fiscal 2027. Holding the 2% gain or moving higher would show that customers are accepting the new rates without switching suppliers.
🐻 Bear Case
Hopewell Factory Drag Keeps Hurting Coatings Margins
"We have completed the critical investments needed to support improved productivity at our plants," Novo said. Yet the Hopewell, Virginia factory — which makes thickeners for architectural paint and construction under the Specialty Additives division — fell short of expectations again. Slow output at Hopewell has dragged down profits for three straight quarters because fixed factory costs are spread over fewer tons of product.
Even though Specialty Additives raised prices 5% and grew coatings sales 9%, segment EBITDA excluding one-offs dropped 31% from a year ago to $20 million. By our math, the segment's margin was 15.3%, barely above the third quarter's 14.7% and nearly 7 percentage points below last year's 22.1%. Ashland blames "lower Hopewell productivity and related unfavorable absorption", and cut its company-wide fiscal 2027 productivity target (called Execute) to just $10 million.
What to watch: Specialty Additives EBITDA margin excluding one-offs in the second quarter of fiscal 2027, when management previously said Hopewell savings would reach the income statement. A reading still stuck near 15% would mean the factory fix is not translating into profit.
The New Plan Points to Lower Cash Flow
Ongoing free cash flow — cash from operations minus factory equipment spending, excluding restructuring and legal payouts — was the highlight of fiscal 2026. It jumped 83% to $232 million, turning 60% of EBITDA excluding one-offs into cash. However, that cash surge happened largely because Ashland shrank its inventory and held back on capital spending after building stock in 2025.
That tailwind reverses next year. For fiscal 2027, the company forecasts cash conversion of "greater than 40 percent", down from 60% this year, "reflecting a modest increase in inventory and capital expenditures of up to approximately $140 million". By our math, a 40% floor at the middle of the new profit range equals $168 million of ongoing free cash flow — a drop of up to 28% even as operating profit grows.
What to watch: capital expenditure and inventory numbers in the first half of fiscal 2027. If equipment spending climbs toward $140 million while Hopewell output lags, free cash flow will tighten.
Risks this quarter didn't answer
Several standing concerns and new corporate charges received little or no detail in the fourth-quarter earnings release.
- Unallocated corporate costs: rose to $18 million excluding one-offs (3.6% of sales vs 2.7% a year ago) on higher bonus and stock pay, and hit $44 million in total on restructuring and an Argentine liquidation, wiping out net income.
- Weak industrial end-markets: energy and resources demand stayed soft and construction volumes fell "resulting from deliberate portfolio actions", leaving a third of the business waiting on a housing recovery.
- Asbestos and environmental payouts: no update in the release text on the roughly $50 million annual cash drain; the annual report will show the year-end reserve totals.
- Board capital allocation committee and credit ratings: no update on the committee formed with activist investor Ancora or on the path back from BB and Ba2 debt ratings.
👓 Other Themes
Stronger US Dollar Will Trim Next Year's Results
Currency exchange rates shifted from a tailwind over the full year to a drag in the fourth quarter, when a stronger US dollar cut sales by $3 million (1%) and EBITDA excluding one-offs by $2 million. Based on recent exchange rates, Ashland's fiscal 2027 outlook builds in a currency drag of $20 million to $25 million on sales (over 1 percentage point of growth) and $7 million to $10 million on profit.
💲 Other KPIs
Net debt — total borrowings minus cash — fell 24% from $1,169 million a year ago as cash on hand more than doubled to $480 million. Net debt now stands at 2.3 times annual EBITDA excluding one-offs, down from 2.4 times in the third quarter and 2.7 times in the first half, keeping the balance sheet comfortably inside management's target range.
Profit in Intermediates — which makes industrial solvents used in electronics, batteries and plastics — rose 20% from $5 million a year ago, reversing a third-quarter decline. Segment margin expanded 3 percentage points to 18.2% as a 5% price increase and higher sales of specialty solvents offset lower volumes, and Ashland expects new battery-storage customers in fiscal 2027.
The diluted share count stayed unchanged at 46 million for a第五 straight quarter. After spending $100 million to buy back shares in the first half of fiscal 2025, the specialty chemicals group made no repurchases during the first nine months of fiscal 2026 and announced none in the fourth-quarter release, leaving $520 million on its buyback authorization.
🔮 Guidance
New. The plan calls for 2% to 6% sales growth (4.1% at the middle of the range), stepping up from 2% reported growth and 3% underlying growth in fiscal 2026. The forecast includes $65 million of combined new-product and geographic expansion targets, partly held back by a $20 million to $25 million currency drag.
New. At the $420 million middle of the range, profit excluding one-offs rises 9.1% from $385 million in fiscal 2026, implying a 21.6% margin (up from 20.7%). However, Ashland cut its initial profit target during each of the last two fiscal years, finishing 9% below the starting midpoint on average.
New. The company sets its cash conversion floor at 40% of EBITDA excluding one-offs, down from 60.3% delivered in fiscal 2026 and a 50% floor in last year's plan. The step-down comes from a planned modest inventory build and capital spending rising to as much as $140 million.
❓ Key Questions
Why is capital spending jumping to $140 million?
Novo said the critical plant investments for productivity are complete, yet the fiscal 2027 outlook raises capital spending to up to $140 million from roughly $90 million targeted in 2026. Investors need to know which projects require the extra $50 million.
When will Hopewell reach its target production rate?
Hopewell's low output cut Specialty Additives profit by 31% in the fourth quarter and caused the Execute programme to miss its full-year goal. Management has not stated the current production rate or how much of the $420 million profit target depends on fixing it.
What splits the $45 million Innovate sales target?
Ashland tripled its Innovate target to $45 million for fiscal 2027 after hosting an innovation event in September. Disclosing how much comes from new launches like oral biologics versus existing cellulosics will show whether the research pipeline is scaling.
Why did Ashland drop the per-share profit outlook?
For fiscal 2026, management guided profit per share growth and missed it (-2.1% actual) after two downward revisions on tax items. The fiscal 2027 outlook omits an earnings per share line entirely, leaving tax and interest assumptions unclear.